Abstract
This report analyzes the worldwide markets for Antivirals in US$ Million. The
major product segments analyzed are HIV Antivirals (Reverse Transcriptase
Inhibitors (RTIs) (Nucleotide Reverse Transcriptase Inhibitors (NRTIs), and
Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs)), and Protease
Inhibitors (PIs), Hepatitis B & C Antivirals (Hepatitis C Antivirals, and
Hepatitis B Antivirals), Herpes Simplex Virus (HSV) Antivirals, Influenza
Antivirals, Respiratory Syncytial Virus (RSV) Antivirals, and Human Papilloma
Virus (HPV) Antivirals. The report provides separate comprehensive analytics
for the US, Japan, Europe and Rest of World. Annual forecasts are provided for
the period of 2000 through 2010. The report profiles 139 companies including
many key and niche players worldwide such as Abbott Laboratories, Boehringer
Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc.,
Hoffmann-La Roche, Merck & Co., Novartis AG, Pfizer Inc., Schering-Plough
Corp. Market data and analytics are derived from primary and secondary
research. Company profiles are mostly extracted from URL research and reported
select online sources.